RecruitingPhase 3NCT03925662
Mebendazole as Adjuvant Treatment for Colon Cancer
Clinical Study Evaluating Mebendazole as Adjuvant Therapy in Patients With Colorectal Cancer
Sponsor
Sherief Abd-Elsalam
Enrollment
40 participants
Start Date
Apr 1, 2019
Study Type
INTERVENTIONAL
Conditions
Summary
mebendazole treating colon cancer
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This study is testing whether mebendazole — an inexpensive antiparasitic medication widely used to treat intestinal worms — can also help slow the growth of stage 4 colorectal cancer when added to standard treatment.
**You may be eligible if...**
- You have stage 4 colorectal cancer (cancer that has spread to other organs)
- You are able to provide informed consent
**You may NOT be eligible if...**
- You have agranulocytosis (a severe condition where white blood cell counts are dangerously low)
- You are pregnant
- You have a known allergy to mebendazole
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGFolfox with avastin
Folfox with avastin only
DRUGMebendazole
Folfox with avastin with mebendazole
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03925662
Related Trials
Reducing Neoplasia Recurrence After Endoscopic Resection of Large Colorectal Polyps
NCT062719411 location
Tislelizumab in People With Colorectal Cancer
NCT065295233 locations
GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular Cancer
NCT07627191
A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors
NCT0600424538 locations
A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer
NCT0752520635 locations